Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...

Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that ...

The Sarepta agreement reduces financial risk and lends credence to Arrowhead's platform. Within this context, Arrowhead appears conservatively valued, at a market capitalization near $2.75 billion.

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

On the other hand, H.C. Wainwright raised Arrowhead's stock price target from $60.00 to $80.00, citing the company's recent global license and collaboration agreement with Sarepta Therapeutics.

Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, Sarepta will pay Arrowhead $500 million upfront and make a $325 ...

Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, consisting of $500M cash and $325M as an equity ...

The financial aspect of the partnership with Sarepta is significant for Arrowhead, with the upfront and equity investments estimated to bolster the company's pro forma cash to $1.5 billion.

Sarepta’s (SRPT) partnership with Arrowhead (ARWR), under which Sarepta will provide $1.4B in upfront, equity, and milestone payments in exchange for exclusive worldwide license of four clinical ...

Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone payments from Sarepta Therapeutics as ...